Last Update 29 Oct 25
Fair value Increased 1.25%Edwards Lifesciences' analyst price target has risen from $87.73 to $88.83. Analysts cite improved transcatheter aortic valve replacement data and heightened confidence in the company's long-term outlook following positive clinical results.
Analyst Commentary
Recent analyst reports on Edwards Lifesciences reflect a range of optimistic and more cautious perspectives in light of new clinical data, market expectations, and the company's valuation trends. These perspectives influence near-term and long-term outlooks for the stock.
Bullish Takeaways- Bullish analysts are encouraged by strong results from the latest transcatheter aortic valve replacement (TAVR) data. These results support the durability and efficacy of Edwards' technology in low-risk patients and may potentially expand its addressable market.
- Positive reception from recent medical conferences has fueled increased confidence in Edwards Lifesciences' execution and long-term growth strategy. This has led to multiple price target increases and rating upgrades.
- Improved real-world data for the Evoque system has been described as a positive development. This suggests upside for the company's share in the transcatheter mitral and tricuspid market.
- Some analysts believe the recent pullback in the stock may be overdone, which presents an attractive valuation and a tactical opportunity for investors ahead of further clinical data releases and earnings updates.
- Cautious analysts highlight that although the latest trial results averted worst-case scenarios, they have not fully alleviated concerns regarding the broader adoption pace of TAVR. This is especially relevant in the context of ongoing physician referral patterns and reimbursement challenges.
- There is ongoing uncertainty about the sustainability of accelerated revenue growth, particularly as competition increases and the large U.S. TAVR market faces maturity.
- Some continue to recommend a more reserved stance and maintain Hold ratings due to lingering risks tied to upcoming data sets and the potential for future estimate revisions.
- Recent calls for lower price targets reflect short-term pressure on shares, which is linked to mixed investor sentiment and concerns over key upcoming data readouts.
What's in the News
- New clinical data from the ENCIRCLE trial demonstrated the safety and effectiveness of Edwards' mitral and tricuspid therapies. One-year outcomes for the SAPIEN M3 transfemoral TMVR system showed low mortality, high rates of mitral regurgitation elimination (95.7% MR = 0/1+), and notable quality-of-life improvements. (Key Developments)
- Results from the EVOQUE system STS/ACC TVT Registry, representing the largest real-world transcatheter tricuspid valve replacement dataset, showed lower pacemaker rates (14.9%), very low major bleeding (1.3%), nearly complete tricuspid regurgitation elimination (98% TR = 0/1+), and swift patient discharges post-procedure. (Key Developments)
- The SAPIEN M3 system was approved in Europe in April 2025. EVOQUE received approval in both the US and Europe. (Key Developments)
- Seven-year data from the PARTNER 3 trial reaffirmed the long-term durability, excellent valve performance, and comparable survival outcomes between SAPIEN 3 TAVR and surgical aortic valve replacement. No significant differences were reported in reintervention or mortality rates. (Key Developments)
- Venus Medtech's Cardiovalve division secured a decisive legal victory over Edwards Lifesciences as a US court upheld the validity of Cardiovalve’s patent related to transcatheter valve therapies, strengthening Venus Medtech's intellectual property position. (Key Developments)
Valuation Changes
- Consensus Analyst Price Target has risen slightly from $87.73 to $88.83, reflecting improved market sentiment.
- Discount Rate increased marginally to 7.47% from 7.42%. This indicates a slightly higher risk premium applied in valuation models.
- Revenue Growth projection edged down minimally from 10.02% to 9.99%.
- Net Profit Margin improved modestly to 23.78% from 23.72%.
- Future P/E ratio rose slightly to 35.49x, up from 35.06x. This suggests a small increase in forward earnings expectations or valuation multiples.
Key Takeaways
- Strategic product launches, like the TAVR approval and EVOQUE, position Edwards for significant revenue growth and expanded market share.
- Investments in surgical innovation and operational efficiency mitigate financial threats, enhance global therapy adoption, and stabilize earnings.
- Tariffs, competitive pressures, and strategic investments could impact Edwards Lifesciences' margins and revenue growth, requiring careful financial planning to achieve targets.
Catalysts
About Edwards Lifesciences- Provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally.
- The expected approval of the early TAVR indication in the second quarter, along with policy and guideline changes in the U.S. and globally, represents a multiyear growth opportunity that could significantly enhance revenue streams in the future.
- The planned launch of the transcatheter tricuspid valve EVOQUE in 2024 is anticipated to uniquely position Edwards to gain market share and increase revenues as it becomes the first company to develop and offer this therapy.
- The recent approval of the Sapien M3 in Europe as the world's first transcatheter mitral valve replacement system signals Edwards' ability to address large, unmet patient needs, which could result in substantial revenue growth.
- Edwards' ongoing investments in surgical innovation, such as the RESILIA tissue technology, are likely to expand access and adoption of its cardiovascular therapies globally, potentially improving net margins and bolstering revenue.
- The company's plan to mitigate the financial impacts of announced tariffs and the JenaValve acquisition while maintaining its EPS guidance of $2.40 to $2.50 demonstrates an operational efficiency that could positively impact earnings.
Edwards Lifesciences Future Earnings and Revenue Growth
Assumptions
How have these above catalysts been quantified?- Analysts are assuming Edwards Lifesciences's revenue will grow by 10.0% annually over the next 3 years.
- Analysts assume that profit margins will shrink from 24.8% today to 23.7% in 3 years time.
- Analysts expect earnings to reach $1.8 billion (and earnings per share of $3.09) by about September 2028, up from $1.4 billion today. However, there is some disagreement amongst the analysts with the more bearish ones expecting earnings as low as $1.5 billion.
- In order for the above numbers to justify the analysts price target, the company would need to trade at a PE ratio of 35.1x on those 2028 earnings, up from 33.2x today. This future PE is greater than the current PE for the US Medical Equipment industry at 29.7x.
- Analysts expect the number of shares outstanding to decline by 0.46% per year for the next 3 years.
- To value all of this in today's terms, we will use a discount rate of 7.42%, as per the Simply Wall St company report.
Edwards Lifesciences Future Earnings Per Share Growth
Risks
What could happen that would invalidate this narrative?- Edwards Lifesciences faces potential financial risks due to the impact of tariffs, which could affect the company's gross margins and net earnings, as they anticipate a $0.05 EPS impact from current tariffs in 2025, with greater impacts expected in 2026.
- The acquisition of JenaValve may lead to an EPS dilution of $0.05 to $0.10, which could strain operating margins and necessitate careful planning to offset the acquisition costs in order to maintain earnings per share targets.
- The competitive pressure in international markets, such as Japan, is exerting downward pressure on TAVR procedure growth, potentially impacting revenue growth and expansion efforts in these regions.
- While Edwards anticipates expanding TAVR indications to asymptomatic patients, the regulatory and policy changes required for this may take longer than expected, delaying the projected revenues from this expanded patient base.
- High levels of discretionary R&D spending, as well as necessary strategic investments to offset EPS impacts, indicate that operating expenses could rise, potentially impacting net profit margins if the expected growth in revenues does not materialize accordingly.
Valuation
How have all the factors above been brought together to estimate a fair value?- The analysts have a consensus price target of $87.731 for Edwards Lifesciences based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $101.0, and the most bearish reporting a price target of just $72.0.
- In order for you to agree with the analyst's consensus, you'd need to believe that by 2028, revenues will be $7.6 billion, earnings will come to $1.8 billion, and it would be trading on a PE ratio of 35.1x, assuming you use a discount rate of 7.4%.
- Given the current share price of $79.8, the analyst price target of $87.73 is 9.0% higher. The relatively low difference between the current share price and the analyst consensus price target indicates that they believe on average, the company is fairly priced.
- We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.
How well do narratives help inform your perspective?
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Read more narratives
There are no other narratives for this company.
View all narratives